Sarepta sinks on delayed NDA, eteplirsen data doubts
This article was originally published in Scrip
Executive Summary
Sarepta Therapeutics's stock sank to its lowest level this year on 27 October, because its new drug application (NDA) submission to the US FDA for eteplirsen will be delayed until mid-2015 while the company responds to new requests for information, including data that could confirm findings from an ongoing Phase II clinical trial in Duchenne muscular dystrophy (DMD).